Suppr超能文献

血清可溶性白细胞介素-2受体在结节病中的临床价值。

The clinical value of serum soluble interleukin-2 receptor in pulmonary sarcoidosis.

作者信息

Ogata-Suetsugu Saiko, Hamada Naoki, Takayama Koichi, Tsubouchi Kazuya, Arimura-Omori Masako, Nakanishi Yoichi

机构信息

Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Department of Pulmonary Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.

出版信息

Sarcoidosis Vasc Diffuse Lung Dis. 2017;34(1):41-47. doi: 10.36141/svdld.v34i1.5045. Epub 2017 Apr 28.

Abstract

Sarcoidosis is a multi-system granulomatous disease in which T-helper type 1 cytokines play a key role. We evaluated the clinical value of serum soluble interleukin-2 receptor (sIL-2R) as a marker of disease activity and prognosis in sarcoidosis. This study included 67 patients who were newly diagnosed with sarcoidosis from 2006 to 2012 at our department. The clinical and follow-up data were retrospectively collected from their medical records. The mean (±SD) age of the patients was 53.9±15.4 years; 41 patients were women and were significantly older than men. Serum angiotensin-converting enzyme had a mean value of 15.3±6.1 U/L and a positive rate of 10.4%. Serum sIL-2R had mean level of 818.8±453.1 U/mL and a positive rate of 45.9%. Moreover, the sIL-2R level of patients who had lung parenchymal lesions was significantly higher than that of patients who had no lung parenchymal lesions. Fifty-two patients who had no medications were followed up at our hospital for a median period of 37 months (range, 0-107 months). Patients who demonstrated chest imaging evidence of exacerbation (n = 8) tended to have higher sIL-2R levels than those who remained stable. Serum sIL-2R may have a role as a diagnostic and prognostic marker in pulmonary sarcoidosis. .

摘要

结节病是一种多系统肉芽肿性疾病,其中1型辅助性T细胞细胞因子起关键作用。我们评估了血清可溶性白细胞介素-2受体(sIL-2R)作为结节病疾病活动和预后标志物的临床价值。本研究纳入了2006年至2012年在我科新诊断为结节病的67例患者。临床和随访数据通过回顾其病历收集。患者的平均(±标准差)年龄为53.9±15.4岁;41例为女性,且显著比男性年龄大。血清血管紧张素转换酶的平均值为15.3±6.1 U/L,阳性率为10.4%。血清sIL-2R的平均水平为818.8±453.1 U/mL,阳性率为45.9%。此外,有肺实质病变患者的sIL-2R水平显著高于无肺实质病变的患者。52例未用药患者在我院接受了中位时间为37个月(范围0 - 107个月)的随访。胸部影像学显示病情加重的患者(n = 8)的sIL-2R水平往往高于病情保持稳定的患者。血清sIL-2R可能在肺结节病中作为诊断和预后标志物发挥作用。

相似文献

1
The clinical value of serum soluble interleukin-2 receptor in pulmonary sarcoidosis.
Sarcoidosis Vasc Diffuse Lung Dis. 2017;34(1):41-47. doi: 10.36141/svdld.v34i1.5045. Epub 2017 Apr 28.
4
Biological role of the soluble interleukin-2 receptor in sarcoidosis.
Sarcoidosis Vasc Diffuse Lung Dis. 2017;34(2):122-129. doi: 10.36141/svdld.v34i2.5369. Epub 2017 Apr 28.
5
ACE and sIL-2R correlate with lung function improvement in sarcoidosis during methotrexate therapy.
Respir Med. 2015 Feb;109(2):279-85. doi: 10.1016/j.rmed.2014.11.009. Epub 2014 Nov 29.

引用本文的文献

1
Diagnostic value of soluble Interleukin-2 receptor in patients suffering neurosarcoidosis: A systematic review.
J Cent Nerv Syst Dis. 2024 Aug 26;16:11795735241274186. doi: 10.1177/11795735241274186. eCollection 2024.
5
Idiopathic granulomatous interstitial nephritis and isolated renal sarcoidosis: Two diagnoses of exclusion.
SAGE Open Med. 2021 Aug 13;9:20503121211038470. doi: 10.1177/20503121211038470. eCollection 2021.
6
Therapeutic Dilemma of Sarcoidosis and Treatment-naïve Hepatitis C Manifesting as Tattoo Reactions.
Intern Med. 2021 Feb 15;60(4):645-650. doi: 10.2169/internalmedicine.5606-20. Epub 2020 Sep 30.
7
Biomarkers in the Diagnosis and Prognosis of Sarcoidosis: Current Use and Future Prospects.
Front Immunol. 2020 Jul 14;11:1443. doi: 10.3389/fimmu.2020.01443. eCollection 2020.

本文引用的文献

1
Age-related and historical changes in the clinical characteristics of sarcoidosis in Japan.
Respir Med. 2015 Feb;109(2):272-8. doi: 10.1016/j.rmed.2014.12.012. Epub 2015 Jan 3.
2
ACE and sIL-2R correlate with lung function improvement in sarcoidosis during methotrexate therapy.
Respir Med. 2015 Feb;109(2):279-85. doi: 10.1016/j.rmed.2014.11.009. Epub 2014 Nov 29.
3
Sarcoidosis: clinical presentation, immunopathogenesis, and therapeutics.
JAMA. 2011 Jan 26;305(4):391-9. doi: 10.1001/jama.2011.10.
4
Comparative evaluation of serum markers in pulmonary sarcoidosis.
Chest. 2010 Jun;137(6):1391-7. doi: 10.1378/chest.09-1975. Epub 2010 Jan 15.
6
Anti-endothelial cell antibodies in patients with sarcoidosis.
Chest. 2008 Apr;133(4):955-60. doi: 10.1378/chest.07-0850.
8
Epidemiology of sarcoidosis in Japan.
Eur Respir J. 2008 Feb;31(2):372-9. doi: 10.1183/09031936.00075307. Epub 2007 Oct 24.
9
Genotype-corrected reference values for serum angiotensin-converting enzyme.
Eur Respir J. 2006 Dec;28(6):1085-90. doi: 10.1183/09031936.00050106.
10
Bronchoalveolar and serological parameters reflecting the severity of sarcoidosis.
Eur Respir J. 2003 Mar;21(3):407-13. doi: 10.1183/09031936.03.00010403.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验